Pyridazinone PARP Inhibitor Compounds, Azkarra Therapeutics, 23rd Apr
Summary
The USPTO published patent application US20260109686A1, filed by Azkarra Therapeutics, Inc. on 2023-10-02 (Application No. 19117032), covering pyridazin-3(2H)-one and pyridin-2(1H)-one core compounds designed to inhibit PARP proteins, particularly PARP7, for treating diseases responsive to PARP inhibition.
Competitors developing PARP inhibitors should treat this publication as prior art and conduct freedom-to-operate analyses. Researchers and investors monitoring oncology therapeutic pipelines should note Azkarra's expanded intellectual property position in the PARP inhibitor space.
“The present disclosure relates to pyridazin-3(2H)-one and pyridin-2(1H)-one core compounds, related compounds, and their use in treating a disease or condition responsive to inhibition of at least one PARP protein.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 229 changes logged to date.
What changed
The USPTO published Azkarra Therapeutics' patent application US20260109686A1 covering pyridazin-3(2H)-one and pyridin-2(1H)-one PARP inhibitor compounds, with claims directed to treating diseases or conditions responsive to PARP protein inhibition, particularly PARP7 and optionally additional PARP proteins. The application, filed October 2, 2023 (Application No. 19117032), names eight inventors.
Competitors in the PARP inhibitor therapeutic space should review this filing for prior art purposes and assess freedom-to-operate implications for their own compounds. Healthcare investors and pipeline analysts tracking oncology research may use this publication to monitor Azkarra's intellectual property strategy in the PARP inhibitor domain.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS
Application US20260109686A1 Kind: A1 Apr 23, 2026
Assignee
Azkarra Therapeutics, Inc.
Inventors
Raymond A. NG, Michael G. JOHNSON, David C. SPELLMEYER, David LAPOINTE, Michael S. COHEN, Guillaume PELLETIER, Dana K. WINTER, Yuchen ZHOU
Abstract
The present disclosure relates to pyridazin-3(2H)-one and pyridin-2(1H)-one core compounds, related compounds, and their use in treating a disease or condition responsive to inhibition of at least one PARP protein. The compounds and methods may be used in treating a disease or condition responsive to inhibition of PARP7 and optionally one or more additional PARP proteins.
CPC Classifications
C07D 403/12 A61K 31/501 A61K 31/502 A61K 31/506 A61K 31/5377 A61K 31/55 A61K 31/551 A61P 35/00 C07D 237/26 C07D 401/12 C07D 401/14 C07D 403/04 C07D 403/14 C07D 413/14 C07D 487/04 C07D 487/08
Filing Date
2023-10-02
Application No.
19117032
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.